Article

COVID-19: Impact of pandemic on Switzerland's ophthalmic space

Author(s):

Alex Delaney-Gesing

Roberto Pinelli, MD, CEO, and founder of the Switzerland Eye Research Institute, shares how operations at the facility have adapted to the growing coronavirus pandemic spreading across the globe.

 

See more coronavirus coverage

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
Related Content
Using opioids to prevent sneezing and potential ocular tissue damage during sedation and periocular injections
August 23rd 2025

Using opioids to prevent sneezing and potential ocular tissue damage during sedation and periocular injections

3 Things You Should Know About the GA Pipeline
August 23rd 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Under-eye filler: Cannula vs needle in tear trough treatment
August 23rd 2025

Under-eye filler: Cannula vs needle in tear trough treatment

Patient-Centered Treatment Strategies in the Management of nAMD and DME
August 23rd 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

European Union flags outside a parliament building. Concept image for European Commission approval and European Medicines Agency regulatory decision on aflibercept biosimilar Mynzepli. Image credit: ©artjazz – stock.adobe.com
August 23rd 2025

European Commission approves aflibercept biosimilar Mynzepli

Nicox releases topline data from phase 3 Denali trial of NCX 470 in open-angle glaucoma or ocular hypertension patients
August 23rd 2025

Nicox releases topline data from phase 3 Denali trial of NCX 470 in open-angle glaucoma or ocular hypertension patients

© 2025 MJH Life Sciences

All rights reserved.